 SHANGHAI and GAITHERSBURG, Md. , July 27, 2021 PRNewswire -- I-Mab the Company Nasdaq: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that on July 27, 2021, the Board of Directors of the Company the Board approved a preliminary proposal for the potential dual listing of the Companys newly issued shares on the Science and Technology Innovation Board of the Shanghai Stock Exchange the STAR Board. 